SEK 0.24
(1.5%)
Year | Inventory | Inventory Growth |
---|---|---|
2022 | - SEK | -100.0% |
2021 | 9.89 Million SEK | -80.78% |
2020 | 51.49 Million SEK | 78.58% |
2019 | 28.83 Million SEK | 122.71% |
2018 | 12.94 Million SEK | 32.85% |
2017 | 9.74 Million SEK | -28.78% |
2016 | 13.68 Million SEK | -17.75% |
2015 | 16.63 Million SEK | 211.51% |
2014 | 5.34 Million SEK | 222.52% |
2013 | 1.65 Million SEK | 86.7% |
2012 | 887 Thousand SEK | 205.86% |
2011 | 290 Thousand SEK | 0.0% |
2010 | - SEK | -100.0% |
2009 | 94 Thousand SEK | -96.61% |
2008 | 2.77 Million SEK | -85.48% |
2007 | 19.12 Million SEK | 4.38% |
2006 | 18.31 Million SEK | 585.14% |
2005 | 2.67 Million SEK | 0.0% |
2004 | - SEK | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2023 Q2 | - SEK | 0.0% |
2023 Q1 | - SEK | 0.0% |
2022 Q2 | 8.91 Million SEK | -9.93% |
2022 Q4 | - SEK | -100.0% |
2022 FY | - SEK | -100.0% |
2022 Q3 | 8.02 Million SEK | -9.95% |
2022 Q1 | 9.89 Million SEK | 0.0% |
2021 Q3 | 16.19 Million SEK | -42.81% |
2021 Q2 | 28.31 Million SEK | -44.82% |
2021 FY | 9.89 Million SEK | -80.78% |
2021 Q1 | 51.32 Million SEK | -0.34% |
2021 Q4 | 9.89 Million SEK | -38.89% |
2020 Q2 | 31.28 Million SEK | 8.48% |
2020 Q4 | 51.49 Million SEK | 4.35% |
2020 FY | 51.49 Million SEK | 78.58% |
2020 Q3 | 49.35 Million SEK | 57.77% |
2020 Q1 | 28.83 Million SEK | 56.85% |
2019 Q4 | 18.38 Million SEK | 11.53% |
2019 Q1 | 12.94 Million SEK | 2.7% |
2019 FY | 28.83 Million SEK | 122.71% |
2019 Q2 | 9.55 Million SEK | -26.24% |
2019 Q3 | 16.48 Million SEK | 72.61% |
2018 Q3 | 11.14 Million SEK | -0.82% |
2018 Q4 | 12.6 Million SEK | 13.16% |
2018 Q2 | 11.23 Million SEK | 15.26% |
2018 FY | 12.94 Million SEK | 32.85% |
2018 Q1 | 9.74 Million SEK | -17.89% |
2017 FY | 9.74 Million SEK | -28.78% |
2017 Q4 | 11.87 Million SEK | -7.96% |
2017 Q3 | 12.89 Million SEK | -4.12% |
2017 Q2 | 13.45 Million SEK | -1.72% |
2017 Q1 | 13.68 Million SEK | -20.82% |
2016 Q1 | 16.63 Million SEK | 30.98% |
2016 FY | 13.68 Million SEK | -17.75% |
2016 Q4 | 17.28 Million SEK | 8.39% |
2016 Q3 | 15.94 Million SEK | -5.75% |
2016 Q2 | 16.91 Million SEK | 1.68% |
2015 Q2 | 6.32 Million SEK | 18.44% |
2015 Q4 | 12.7 Million SEK | 120.61% |
2015 Q1 | 5.34 Million SEK | 101.09% |
2015 FY | 16.63 Million SEK | 211.51% |
2015 Q3 | 5.75 Million SEK | -8.98% |
2014 Q1 | 1.65 Million SEK | 785.56% |
2014 Q4 | 2.65 Million SEK | -4.05% |
2014 Q3 | 2.76 Million SEK | 1.88% |
2014 Q2 | 2.71 Million SEK | 64.07% |
2014 FY | 5.34 Million SEK | 222.52% |
2013 Q1 | 887 Thousand SEK | 761.17% |
2013 FY | 1.65 Million SEK | 86.7% |
2013 Q3 | 1.85 Million SEK | 108.91% |
2013 Q4 | 187 Thousand SEK | -89.91% |
2013 Q2 | 887 Thousand SEK | 0.0% |
2012 Q1 | 290 Thousand SEK | 0.0% |
2012 Q4 | 103 Thousand SEK | -88.39% |
2012 FY | 887 Thousand SEK | 205.86% |
2012 Q2 | 887 Thousand SEK | 205.86% |
2012 Q3 | 887 Thousand SEK | 0.0% |
2011 Q3 | 32 Thousand SEK | 0.0% |
2011 Q2 | - SEK | 0.0% |
2011 Q4 | 290 Thousand SEK | 806.25% |
2011 FY | 290 Thousand SEK | 0.0% |
2011 Q1 | - SEK | -100.0% |
2010 Q4 | 94 Thousand SEK | 0.0% |
2010 FY | - SEK | -100.0% |
2010 Q3 | 94 Thousand SEK | 0.0% |
2010 Q2 | 94 Thousand SEK | 0.0% |
2010 Q1 | 94 Thousand SEK | 0.0% |
2009 FY | 94 Thousand SEK | -96.61% |
2008 FY | 2.77 Million SEK | -85.48% |
2007 FY | 19.12 Million SEK | 4.38% |
2006 FY | 18.31 Million SEK | 585.14% |
2005 FY | 2.67 Million SEK | 0.0% |
2004 FY | - SEK | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
AcuCort AB | -1.09 Million SEK | 100.0% |
AlzeCure Pharma AB (publ) | -2508.00 SEK | 100.0% |
BioGaia AB (publ) | 181.2 Million SEK | 100.0% |
Enzymatica AB (publ) | 11.49 Million SEK | 100.0% |
Enorama Pharma AB (publ) | 4.29 Million SEK | 100.0% |
Gabather AB (publ) | -1772.00 SEK | 100.0% |
Klaria Pharma Holding AB (publ.) | - SEK | NaN% |
Moberg Pharma AB (publ) | 7.11 Million SEK | 100.0% |
Nanexa AB (publ) | 1.91 Million SEK | 100.0% |
Newbury Pharmaceuticals AB (publ) | 4.99 Million SEK | 100.0% |
ODI Pharma AB | - SEK | NaN% |
Orexo AB (publ) | 42.4 Million SEK | 100.0% |
Probi AB (publ) | 116.7 Million SEK | 100.0% |
Swedencare AB (publ) | 398.1 Million SEK | 100.0% |
Swedish Orphan Biovitrum AB (publ) | 3.87 Billion SEK | 100.0% |
Toleranzia AB | -1.34 Million SEK | 100.0% |